Intensified Induction Therapy for Newly Diagnosed, Localized Skeletal Ewing Sarcoma (ISG/AIEOP EW-1): A Randomized,...

Area of Science:

• Pediatric Oncology
• Medical Oncology
• Clinical Trials

Background:

• Treatment intensity impacts outcomes in Ewing sarcoma.
• Standard treatment for non-metastatic Ewing sarcoma is 37 weeks.
• An intensive, shorter chemotherapy regimen (25 weeks) was evaluated.

Purpose of the Study:

• To test the non-inferiority of an intensive, shorter induction chemotherapy regimen compared to standard treatment for localized Ewing sarcoma.
• To evaluate event-free survival (EFS) and toxicity profiles of both treatment arms.

Main Methods:

• A national, multicenter, randomized, phase III non-inferiority trial.
• 233 patients with localized Ewing sarcoma were randomized into standard (Arm A) and intensive (Arm B) arms.
• Treatment arms differed in consolidation therapy duration for good responders.

Main Results:

• Arm B (intensive) was non-inferior to Arm A (standard) with 5-year EFS of 77.5% vs. 71.6%.
• Good responders were higher in Arm B (62.5%) compared to Arm A (54.9%).
• Arm B showed higher rates of Grade ≥3 hematological, gastrointestinal, and cardiovascular toxicities.

Conclusions:

• Intensive induction chemotherapy is non-inferior to standard therapy for 5-year EFS in localized Ewing sarcoma.
• The intensive regimen offers a shorter treatment plan, particularly beneficial for good responders.
• Increased toxicity in the intensive arm requires careful consideration against the benefits of a shorter treatment duration.